Vaccine after colon cancer surgery to lower return risk
Part of Cancer, Digestive system clinical trials.
This phase 3 study tests whether an “oncol” vaccine (OncoVax®) given after curative surgery can help keep stage II colon cancer from coming back. It’s for people whose surgery successfully removed the cancer and who have normal tumor marker levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage II colon cancer (IIA, IIB, or IIC as defined by tumor and lymph node findings).
- You already had surgery to completely remove the cancer, and scans show no remaining or spread (metastatic) disease.
- Your CEA blood test (a cancer marker) is currently normal; if it was high before surgery, it must return to normal within 21 days after surgery.
- You have not had chemotherapy or radiation before joining the study.
- You should not have had a prior cancer, except skin cancers treated as “cured” (squamous cell or basal cell) or cervical carcinoma in situ.
- You have only one primary colon cancer (not more than one).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests immunotherapy plus chemotherapy given before surgery for colon cancer that hasn’t spread. It aims to shrink or control the tumor and improve outcomes in people whose tumor has certain immune/biologic features.
This phase 2 trial tests whether injecting a vaccine into the tumor, along with pembrolizumab (an immune medicine), can improve outcomes for people with early-stage, localized colon cancer that does not have certain DNA mismatch repair changes (pMMR). It’s done around the time you plan to have curative surgery, with the goal of boosting the immune system against the cancer.
This study looks at colon cancer that comes back in the same area after surgery. It may help doctors understand how to better treat this type of recurrence.
This trial tests whether a personalized vaccine—made from your own immune cells mixed with your own tumor material—can help prevent colorectal cancer from coming back after curative surgery. It may help your immune system recognize and fight any remaining cancer cells.
This trial tests whether a drug called an immune checkpoint inhibitor (PD-1 blocker) can help lower the risk of cancer returning after surgery. It is for people with a specific type of colorectal cancer (dMMR or MSI-H) that had certain high-risk features.
This trial tests a custom-made vaccine designed from your tumor's genetic material. The vaccine is given alongside standard chemotherapy and an immunotherapy drug to try to prevent the cancer from coming back. It is for people with stage 3 colorectal cancer that has been fully removed by surgery and has certain high-risk features.
Hear when a new Stage II Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.